Cardio Diagnostics Holdings, Inc. (CDIO)
| Market Cap | 12.26M |
| Revenue (ttm) | 32,993 |
| Net Income (ttm) | -11.51M |
| Shares Out | 22.69M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,146 |
| Open | 0.531 |
| Previous Close | 0.540 |
| Day's Range | 0.531 - 0.560 |
| 52-Week Range | 0.171 - 3.560 |
| Beta | 5.06 |
| Analysts | Buy |
| Price Target | 2.00 (+270.03%) |
| Earnings Date | Aug 12, 2024 |
About CDIO
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois. [Read more]
Financial Performance
In 2023, CDIO's revenue was $17,065, an increase of 1696.32% compared to the previous year's $950. Losses were -$8.38 million, 79.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CDIO stock is "Buy" and the 12-month stock price forecast is $2.0.
News
Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' clinical blood test, Epi+Gen CHD is now available at FMS' retail clinical location at the Meijer Supercenter in McHenry, IL.
Cardio Diagnostics Announces It's Exhibiting at the 2024 Onsite Employee Health Clinics Forum
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum.
Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit.
Cardio Diagnostics to Participate in the Centers for Medicare and Medicaid Services' (CMS) Clinical Laboratory Fee Schedule (CLFS) Annual Meeting to Secure Medicare Payment for Its Innovative Tests
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will recommend pricing for its Epi+Gen CHD and PrecisionCHD tests, and pursue coverage via the MolDx program.
Cardio Diagnostics Holdings, Inc. Announces the Availability of Its Clinical Tests at Family Medicine Specialists' Retail Healthcare Clinic at Walmart Supercenter in Round Lake Beach, Illinois, That Offers Walk-In Appointments Seven Days a Week
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' clinical blood tests are now available at FMS' newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois.
Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually
CHICAGO--(BUSINESS WIRE)--New study finds that Cardio Diagnostics' PrecisionCHD™ test could save health insurers over $113 Million per year.
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan
CHICAGO--(BUSINESS WIRE)--Exponential Health adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests marking a new era in personalized and preventive cardiac care.
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre
CHICAGO--(BUSINESS WIRE)--This collaboration aims to expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests.
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology's 73rd Annual Scientific Session
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its HeartRisk and Actionable Clinical Intelligence platforms at the ACC's 73rd Annual Scientific Session.
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced the issuance of its second U.S. patent.
Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.
Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' AI-driven epigenetic-genetic blood tests will be available Q2 2024 inside the Walmart Supercenter in Round Lake Beach, Illinois.
Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests
CHICAGO--(BUSINESS WIRE)--resTOR Longevity Clinic will offer Cardio Diagnostics' blood-based epigenetic-genetic cardiovascular disease tests.
Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor.
Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that India's Patent Office has granted a patent to the University of Iowa Research Foundation under patent number 484488.
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform.
Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform.
American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
CHICAGO--(BUSINESS WIRE)--The AMA has granted and assigned Cardio Diagnostics a dedicated CPT® PLA for the company's AI-driven CHD event risk assessment test, Epi+Gen CHD.
American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.'s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that the AMA has assigned a dedicated CCPT® PLA) for the company's AI-driven CHD detection test, PrecisionCHD.
Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director.
Cardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. today announced it has regained Nasdaq minimum bid price requirement.
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference.
Cardio Diagnostics Holdings, Inc's Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference.
American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc's Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the AMA CPT Editorial Panel is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT PLA codes.
Cardio Diagnostics Holdings, Inc. Announces Breakthrough in Coronary Heart Disease Detection with PrecisionCHD Test, Published in the Journal of the American Heart Association
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA),.